Calcium Channel Blocker News and Research

RSS
Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia

Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia

Two drug combo blood pressure therapy lowers cardiovascular risk

Two drug combo blood pressure therapy lowers cardiovascular risk

Diltiazem reduces cocaine cravings in a rat model

Diltiazem reduces cocaine cravings in a rat model

Calcium channel blockers cut risk of Parkinson's disease

Calcium channel blockers cut risk of Parkinson's disease

Evidence strongly supports diuretics as initial metabolic syndrome therapy, especially in black patients

Evidence strongly supports diuretics as initial metabolic syndrome therapy, especially in black patients

Gene variations associated with effectiveness of blood pressure medications

Gene variations associated with effectiveness of blood pressure medications

More effective method of treating high blood pressure

More effective method of treating high blood pressure

Top five prescribed drugs

Top five prescribed drugs

Are there gender differences in management modalities?

Are there gender differences in management modalities?

Lupin receives approval for Amlodipine tablets

Lupin receives approval for Amlodipine tablets

Medicare Part D plans vary across U.S.

Medicare Part D plans vary across U.S.

Isradipine may slow Parkinson's

Isradipine may slow Parkinson's

Isradipine shown to slow down Parkinson's disease

Isradipine shown to slow down Parkinson's disease

Combination of medicines best for blood pressure control

Combination of medicines best for blood pressure control

Single-tablet combination of atorvastatin and amlodipine for high blood pressure effective

Single-tablet combination of atorvastatin and amlodipine for high blood pressure effective

Raynaud's disease review by Mayo Clinic Health Letter

Raynaud's disease review by Mayo Clinic Health Letter

Caraco Pharmaceuticals to market generic Nimotop

Caraco Pharmaceuticals to market generic Nimotop

Neuromed licenses chronic pain product from ALZA Corporation

Neuromed licenses chronic pain product from ALZA Corporation

Trial of percutaneous coronary intervention added to optimal medical therapy in patients with stable coronary heart disease

Trial of percutaneous coronary intervention added to optimal medical therapy in patients with stable coronary heart disease

Novel anti-oxidant and anti-inflammatory agent reduces coronary events

Novel anti-oxidant and anti-inflammatory agent reduces coronary events

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.